These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
167 related items for PubMed ID: 11757848
1. European experience with oral solution and intravenous itraconazole. Potter M. Oncology (Williston Park); 2001 Nov; 15(11 Suppl 9):27-32. PubMed ID: 11757848 [Abstract] [Full Text] [Related]
2. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients. Kibbler CC. Mycoses; 1999 Nov; 42 Suppl 2():121-4. PubMed ID: 10865918 [Abstract] [Full Text] [Related]
3. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Lass-Flörl C, Gunsilius E, Gastl G, Englisch M, Koch G, Ulmer H, Dierich MP, Petzer A. Ann Hematol; 2003 Sep; 82(9):565-9. PubMed ID: 14504812 [Abstract] [Full Text] [Related]
4. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. Myoken Y, Sugata T, Kyo T, Fujihara M, Mikami Y. J Periodontol; 2002 Jan; 73(1):33-8. PubMed ID: 11846198 [Abstract] [Full Text] [Related]
5. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K. Clin Infect Dis; 2001 Oct 15; 33(8):e83-90. PubMed ID: 11550120 [Abstract] [Full Text] [Related]
6. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol. Castagnola E, Bucci B, Montinaro E, Viscoli C. Bone Marrow Transplant; 1996 Nov 15; 18 Suppl 2():97-106. PubMed ID: 8932808 [Abstract] [Full Text] [Related]
7. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G, Spector N, Derossi A, Pulcheri W. Clin Infect Dis; 2000 Feb 15; 30(2):300-5. PubMed ID: 10671332 [Abstract] [Full Text] [Related]
8. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K. Antimicrob Agents Chemother; 2000 Jul 15; 44(7):1887-93. PubMed ID: 10858349 [Abstract] [Full Text] [Related]
9. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C, Pasold R, Wolf HH, Hänel M, Dölken G, Junghanss C, Andreesen R, Bertz H, Itraconazole Research Group of Germany. J Antimicrob Chemother; 2006 Feb 15; 57(2):317-25. PubMed ID: 16339606 [Abstract] [Full Text] [Related]
10. Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole. Watanabe N, Matsumoto K, Kojima S, Kato K. J Pediatr Hematol Oncol; 2011 May 15; 33(4):270-5. PubMed ID: 21464763 [Abstract] [Full Text] [Related]
12. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. Glasmacher A, Prentice AG. J Antimicrob Chemother; 2005 Sep 15; 56 Suppl 1():i23-i32. PubMed ID: 16120631 [Abstract] [Full Text] [Related]
13. Strategies for managing systemic fungal infection and the place of itraconazole. Potter M. J Antimicrob Chemother; 2005 Sep 15; 56 Suppl 1():i49-i54. PubMed ID: 16120634 [Abstract] [Full Text] [Related]
14. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. Warn PA, Sharp A, Morrissey G, Denning DW. Int J Antimicrob Agents; 2010 Feb 15; 35(2):146-51. PubMed ID: 20015618 [Abstract] [Full Text] [Related]
15. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Caillot D. Acta Haematol; 2003 Feb 15; 109(3):111-8. PubMed ID: 12714819 [Abstract] [Full Text] [Related]
16. Management of mycoses in surgical patients -- review of the literature. Holzheimer RG, Dralle H. Eur J Med Res; 2002 May 31; 7(5):200-26. PubMed ID: 12069912 [Abstract] [Full Text] [Related]
17. A brief review of antifungal therapy for deep fungal infection. Muller RJ. Oncology (Williston Park); 2001 Nov 31; 15(11 Suppl 9):21-5. PubMed ID: 11757847 [Abstract] [Full Text] [Related]
18. Current management of fungal infections. Meis JF, Verweij PE. Drugs; 2001 Nov 31; 61 Suppl 1():13-25. PubMed ID: 11219547 [Abstract] [Full Text] [Related]
19. Antifungal prophylaxis in neutropenic patients with hematologic malignancies. Böhme A, Karthaus M, Hoelzer D. Antibiot Chemother (1971); 2000 Nov 31; 50():69-78. PubMed ID: 10874456 [No Abstract] [Full Text] [Related]
20. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albós A. Haematologica; 1997 Nov 31; 82(3):297-304. PubMed ID: 9234575 [Abstract] [Full Text] [Related] Page: [Next] [New Search]